Clavic-Q-RE is a next-generation autologous cancer immunotherapy, designed by RGCC and offered through Neeli Genetics. It leverages your body’s own immune cells, trained and activated in the lab to specifically target cancer cells based on your unique molecular and genetic profile. This is cancer care personalised not just by your DNA but by your immune fingerprint.
Clavic-Q-RE is developed from your own immune cells. After a blood sample is collected, RGCC’s advanced labs isolate and train your natural killer (NK) cells and cytotoxic T-cells to recognize your specific tumor antigens. This immune cell “education” is guided by molecular profiling including your:
Once activated, your own immune cells are re-infused, and they seek out and destroy cancer cells with high precision and minimal collateral damage.
Clavic-Q-RE enhances your immune system’s innate intelligence by:
It is especially effective for patients who have failed standard chemotherapy or those with high levels of immune evasion or checkpoint suppression.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.